Biofrontera Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Biofrontera is a U.S.-based biopharmaceutical company focused on dermatology. Ameluz is its principal product; revenue from Xepi and related-party lamp services was described as insignificant.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Net revenue | $7.912 million | $8.733 million |
| Operating loss | $5.467 million | $5.492 million |
| Net loss | $10.437 million | $7.478 million |
| Loss per share, basic and diluted | $2.88 | $5.60 |
| Cash used in operating activities | $3.325 million | $3.689 million |
| Cash and cash equivalents | $3.817 million | $1.343 million at Dec. 31, 2023 |
| Current liabilities | $14.036 million | $18.088 million at Dec. 31, 2023 |
| Short-term debt | $2.355 million | $3.904 million at Dec. 31, 2023 |
| Total liabilities | $26.421 million | $23.139 million at Dec. 31, 2023 |
| Accumulated deficit | $110.087 million | $99.650 million at Dec. 31, 2023 |
Net product revenue was $7.901 million. The filing’s reported cost-of-revenue presentation separates related-party costs from other costs; it does not provide a single clearly stated gross margin for Q1. Management expects Ameluz gross margins of approximately 75% on inventory purchased after the February 2024 license amendment, versus approximately 50% previously.
Adjusted EBITDA, a non-GAAP measure, was a loss of $4.577 million, compared with a loss of $4.129 million; adjusted EBITDA margin was negative 57.9%, versus negative 47.3%.
Material changes and financing
- Revenue fell $0.821 million, or 9.3%, year over year, primarily due to lower Ameluz volume. Management cited the Change Healthcare cybersecurity incident and resulting reimbursement delays as contributing factors.
- Net loss increased by $2.959 million. Major year-over-year items included a $3.429 million non-cash warrant-liability loss, versus a $1.028 million gain in 2023, and net interest expense of $1.407 million, versus $0.035 million. These were partly offset by the prior-year $2.941 million investment loss not recurring at a comparable scale.
- Q1 financing cash flow was $5.799 million, including proceeds from a preferred-stock and warrant placement, offset by debt repayments. The notes report approximately $7.3 million net proceeds from the preferred placement.
- After quarter-end, investors exercised the Series B-3 preferred warrants on May 13–14, 2024, generating approximately $7.4 million net proceeds. The company reported that all such warrants had been exercised by May 15.
- Common shares outstanding increased to 5,089,413 at March 31, from 1,517,628 at year-end, following pre-funded warrant exercises and preferred-stock conversion. Preferred securities and warrants carry significant potential dilution; the filing identifies millions of additional common shares issuable upon conversion, subject to their terms.
Liquidity, outlook and risks
- Going concern: Management disclosed that conditions raised substantial doubt about the company’s ability to continue as a going concern for at least 12 months, but believes its plans alleviate that doubt. Those plans include the preferred financing, the subsequent $7.4 million warrant exercise, the amended Ameluz agreement, sales growth and cost controls. Management’s assessment depends on execution and other financing being available if needed.
- Cost reductions and margins: The 2024 budget targets approximately $5.5 million less discretionary spending than in 2023. The amended Ameluz license reduces the transfer price to 25% through 2025, with scheduled increases thereafter; management expects approximately $1.5 million in net savings through May 2025, partly offset by increased R&D costs.
- Debt: Two loans originally totaling $4.0 million carry a stated 44% interest rate and require weekly principal-and-interest payments through July 5, 2024. They are secured by substantially all company assets. Q1 net interest expense was $1.407 million. The company also terminated its Midcap credit facility in January, recording a $0.316 million extinguishment loss.
- Commercial and supply outlook: Management expects Xepi commercial supply in Q4 2024 after manufacturing delays and expects to launch RhodoLED XL in Q2 2024. Timing and supply remain uncertain. A limited Ameluz packaging recall was initiated by the licensor; the licensor indicated the product was not likely to cause adverse health consequences and is responsible for replacement costs.
- Legal and contractual matters: The company is defending a lawsuit alleging Ameluz promotion inconsistent with FDA labeling. It cannot estimate the likelihood or range of a material loss; an adverse outcome could materially affect results. From 2025, minimum Ameluz purchase commitments apply, and failure to meet annual minimums may trigger termination rights. The license also includes minimum R&D funding provisions for 2025–2030.
- Listing status: Nasdaq had previously notified the company of noncompliance with its $2.5 million stockholders’ equity requirement. The company said it was above the threshold as of the filing date following cost reductions and equity financing. Stockholders approved an increase in authorized common shares to 35 million in April 2024.
Most important facts for investors to verify
- Whether Ameluz sales recover from Q1’s decline and whether management achieves its sales and spending plans.
- Cash runway after Q1 operating cash burn, subsequent financing, and the near-term high-cost loan repayments.
- Actual Ameluz gross margins and savings under the amended license, including the impact of increased R&D responsibilities and future transfer-price increases.
- Potential dilution, preferred-stock conversion and redemption terms, and the effect of the expanded authorized share count.
- Progress on Xepi supply and the RhodoLED XL launch, and any further manufacturing or reimbursement disruptions.
- Developments in the promotional-practices lawsuit, Nasdaq compliance, and contractual minimum-purchase and R&D obligations.